^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ilumya (tildrakizumab-asmn)

    i
    Other names: SUNPG1623, SCH 900222, MK 3222, SCH 900223, SCH-900222, SUNPG 1622, SUNPG 1622 I, MK-3222 , MK3222
    Associations

    News

    Trials
    Company:
    Almirall, China Medical System, Hikma, Merck (MSD), Sun Pharma
    Drug class:
    IL-23 antagonist
    Associations

    News

    Trials
    18d
    A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (clinicaltrials.gov)
    P2/3, N=135, Active, not recruiting, Sun Pharmaceutical Industries Limited | Recruiting --> Active, not recruiting | Trial completion date: Dec 2031 --> Aug 2031 | Trial primary completion date: Jul 2025 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Ilumya (tildrakizumab-asmn)
    24d
    BeNeBio: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (clinicaltrials.gov)
    P4, N=244, Completed, Radboud University Medical Center | Active, not recruiting --> Completed
    Trial completion • Head-to-Head
    |
    IL17A (Interleukin 17A)
    |
    Cosentyx (secukinumab) • Ilumya (tildrakizumab-asmn)
    25d
    Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators. (PubMed, Proc (Bayl Univ Med Cent))
    The immunomodulatory agents assessed included adalimumab, infliximab, ixekizumab, secukinumab, tildrakizumab, certolizumab pegol, risankizumab, etanercept, guselkumab, and ustekinumab. Overall, IL-23 inhibitors risankizumab, guselkumab, and ustekinumab had the greatest decreased risk of PsA. Physicians can consider risankizumab, guselkumab, and ustekinumab as treatment options for psoriasis patients with PsA risk factors to mitigate disease progression and improve patients' quality of life.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • JAK1 (Janus Kinase 1) • JAK3 (Janus Kinase 3) • IL23A (Interleukin 23 Subunit Alpha)
    |
    Cosentyx (secukinumab) • Ilumya (tildrakizumab-asmn)
    1m
    Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (clinicaltrials.gov)
    P3, N=296, Active, not recruiting, Sun Pharmaceutical Industries Limited | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Sep 2025 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Ilumya (tildrakizumab-asmn)
    1m
    Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis (clinicaltrials.gov)
    P3, N=529, Active, not recruiting, Sun Pharmaceutical Industries Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Ilumya (tildrakizumab-asmn)
    2ms
    IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? (PubMed, J Inflamm Res)
    Although all three agents demonstrate high and durable effectiveness, real-world data suggest subtle intraclass differences, with guselkumab and risankizumab often achieving faster or deeper early responses, and tildrakizumab offering greater dosing flexibility with comparable long-term persistence in selected patient profiles. Overall, IL-23 blockade has evolved from a highly effective trial-based strategy into a versatile and reliable long-term therapeutic approach capable of addressing unmet needs in routine clinical practice.
    Review • Journal
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    Ilumya (tildrakizumab-asmn)
    2ms
    Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors. (PubMed, Dermatol Reports)
    PE has been reported with anti-tumor necrosis factor (TNF)-α, anti-interleukin (IL)-17, and more recently with anti-IL-23 agents such as risankizumab, tildrakizumab, and guselkumab, with an estimated incidence of 1-3% among psoriatic patients treated with biologics, likely underestimated. Herein, we report the successful use of upadacitinib, an oral selective Janus kinase (JAK)-1 inhibitor approved for both psoriatic arthritis and atopic dermatitis, in the management of a PE induced by guselkumab. [...].
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL23A (Interleukin 23 Subunit Alpha)
    |
    Ilumya (tildrakizumab-asmn)
    3ms
    Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Sun Pharmaceutical Industries Limited | Trial completion date: Dec 2025 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    Ilumya (tildrakizumab-asmn)
    3ms
    Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)
    P4, N=10, Not yet recruiting, University of California, San Francisco
    New P4 trial
    |
    5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • cyclosporine • roflumilast • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn) • chloroquine phosphate
    3ms
    Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) (clinicaltrials.gov)
    P3, N=508, Completed, Sun Pharmaceutical Industries Limited | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    Ilumya (tildrakizumab-asmn)
    3ms
    Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (clinicaltrials.gov)
    P3, N=296, Active, not recruiting, Sun Pharmaceutical Industries Limited | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    Ilumya (tildrakizumab-asmn)
    3ms
    Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) (clinicaltrials.gov)
    P3, N=508, Active, not recruiting, Sun Pharmaceutical Industries Limited | Trial primary completion date: Sep 2025 --> Mar 2025
    Trial primary completion date
    |
    Ilumya (tildrakizumab-asmn)